The estrogen receptor as a mediator of the pathological actions of cholesterol in breast cancer
Author:
Publisher
Informa UK Limited
Subject
Obstetrics and Gynaecology,General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.3109/13697137.2014.966949
Reference49 articles.
1. Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline
2. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer
3. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial
4. Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Circulating 27-hydroxycholesterol, lipids, and steroid hormones in breast cancer risk: a nested case–control study of the Multiethnic Cohort Study;Breast Cancer Research;2023-08-14
2. The Molecular and Genetic Interactions between Obesity and Breast Cancer Risk;Medicina;2023-07-21
3. Post-diagnostic statin use and breast cancer-specific mortality: a population-based cohort study;Breast Cancer Research and Treatment;2023-03-17
4. Statin use in patients with hormone receptor‐positive metastatic breast cancer treated with everolimus and exemestane;Cancer Medicine;2022-10-19
5. Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer;Marine Drugs;2022-05-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3